Bharat Biotech on Monday announced that it has completed clinical development for phase III trials and booster doses for BBV154 intranasal covid vaccine.
Speaking about the same, the Hyderabad-based company said, “BBV154 has proven to be safe, well-tolerated & immunogenic in subjects in controlled clinical trials.".